First Wholly A.I.-created Drug INS018_055 for Pulmonary Fibrosis Enters Clinical Trials

  • Hong Kong-based startup Insilico Medicine develops first wholly A.I.-created drug INS018_055, targeting idiopathic pulmonary fibrosis.
  • The discovery process started in 2020 with hopes to overcome challenges with current treatments, after receiving over $400 million in funding.
  • Following successful Phase II trials, the company plans to expand the testing population across sites in the U.S. and China.
Join 2 million subscribers

A curated newsletter that summarizes the important news at the intersection of Global tech, India Tech and AI.

Delivered 8 AM. Daily.
nextbigwhat We would like to show you notifications for the latest news and updates.
Allow Notifications